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Abstract: Although current recommendations for the treatment of advanced non-small cell lung cancer (NSCLC) include a maximum 
of six cycles of platinum-based combination therapy as a first-line approach, most patients experience progression within 3–4 months. 
Therefore, a new treatment strategy, maintenance therapy, has been proposed, and several large randomized prospective controlled tri-
als have shown benefits with maintenance therapy. Maintenance therapy can be classified as either continuation maintenance, which is 
defined as a prolongation of a part of the first-line chemotherapy or molecularly targeted agent until progression, or switch-maintenance, 
which is defined as the administration of a different cytotoxic chemotherapy or molecularly targeted agent immediately after induction 
therapy. In this article, recent results from large randomized phase III trials regarding maintenance therapy are reviewed in order to 
evaluate the role of maintenance therapy in NSCLC.
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Introduction
Lung cancer is the leading cause of cancer death 
worldwide.1 Non-small cell lung cancer (NSCLC) 
accounts for 80% of lung cancer diagnoses, and 
the majority of patients with NSCLC present with 
locally advanced or metastatic disease. Platinum-
based doublet chemotherapy has been considered 
the  gold  standard  for  first-line  pharmacother-
apy for advanced NSCLC, giving rise to modest 
increases in survival and symptom improvement. 
Current  guidelines  by  the  American  Society  of 
Clinical  Oncology  for  patients  with  advanced 
stage IV NSCLC include a maximum of six cycles 
of  platinum-based  doublets  based  on  the  results 
of  several  randomized  trials  and  meta-analyses, 
  demonstrating  that    prolonged  periods  of  admin-
istration of platinum-based chemotherapy did not 
improve overall survival (OS).2–6 Nevertheless, most 
patients experience progression within 3–4 months 
after 4–6 cycles of first-line therapy. Therefore new 
treatment strategies, such as maintenance therapy 
are needed to delay disease progression, to prevent 
symptom deterioration, to maintain patients’ per-
formance status to allow further therapy, and even-
tually to increase OS. Maintenance therapy can be 
classified as either continuation maintenance, which 
is defined as a prolongation of a part of the   first-line 
chemotherapy  or  molecularly  targeted  agent 
until  progression,  or  switch-maintenance,  which 
is  defined  as  the  administration  of  a  different 
  cytotoxic  chemotherapy  or  molecularly  targeted 
agent  immediately  after  induction  therapy.  In 
this article, recent results from large randomized 
phase III   trials regarding maintenance therapy are 
reviewed in order to evaluate the role of mainte-
nance therapy in NSCLC.
Materials and Methods
The  following  key  words  were  used  for  PubMed 
search;  non-small  cell  lung  cancer,  maintenance, 
  chemotherapy,  gefitinib,  erlotinib,  cetuximab,  and 
antiagiogenic.  Also  the  proceeding  of  American 
  Society of Clinical Oncology annual meeting, the pro-
ceedings of European Society of Medical   Oncology, 
and the proceedings of World Conferences on Lung 
  Cancer from 2003 to 2011 were searched. Only arti-
cles   written in the English language were eligible. 
Phase  III    randomized  studies  were  preferentially 
selected for this review.
continuation Maintenance Therapy
Continuation maintenance  
with a cytotoxic agent
Prolonged use of platinum-based doublet   chemotherapy 
increases toxicity without survival benefit, and most 
patients cannot tolerate such an approach. Therefore, 
the continuation of non-platinum cytotoxic chemo-
therapy  has  been  actively  investigated  in  patients 
who achieve at least stable disease (SD) with induc-
tion therapy.
Belani et al performed a large randomized trial of 
paclitaxel  maintenance  after  induction  using    various 
combinations of carboplatin and paclitaxel. Patients who 
responded after four cycles of induction chemotherapy 
were randomized to receive weekly   maintenance doses 
of paclitaxel or best supportive care (BSC).7 The   primary 
endpoint of this study was time to progression (TTP). 
The median TTP in the paclitaxel arm was 38 weeks 
compared with 29 weeks in the BSC arm (P = 0.124) 
with no difference in median OS (75 vs. 60 weeks, 
P = 0.243). Of note, only 23% of patients completed 
four cycles of paclitaxel, and 45% experienced at least 
one grade 3 or 4 adverse event.
A randomized phase III multicenter trial of gemcit-
abine maintenance therapy after a combination of gem-
citabine and cisplatin in 350 patients with advanced 
NSCLC was conducted by Brodowicz et al.8 Patients 
who achieved at least SD were randomized in a 2:1 
ratio to receive maintenance gemcitabine plus BSC or 
BSC alone. The primary endpoint was TTP, and the 
secondary endpoints included overall response rate, 
response duration, OS, toxicity, and symptom control. 
Two  hundred  fifteen  patients  were  randomized  to 
gemcitabine maintenance or BSC; finally, 138 patients 
were treated with gemcitabine and 68 were treated 
with BSC. The median TTP as the primary endpoint 
was significantly prolonged in the gemcitabine main-
tenance arm at 6.6 months compared with 5 months in 
the BSC group (P , 0.001). However, there was no 
difference in OS between the gemcitabine and BSC 
arms (13 vs. 11 months, P = 0.195). Although gem-
citabine was well tolerated, patients receiving gemcit-
abine required a greater number of transfusions than 
the BSC group (20% vs. 6.3% P = 0.018).effectiveness of pharmacotherapies for lung cancer
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Gemcitabine  maintenance  after  induction  of 
gemcitabine and carboplatin has also been reported. 
Of 519 patients, 128 patients with a stable or partial 
response were randomized to gemcitabine mainte-
nance and 127 were randomized to BSC.9 The primary 
endpoint was progression-free survival (PFS). There 
was no difference in PFS or OS (7.4 vs. 7.7 months 
for PFS; 8.0 vs. 9.3 months for OS) between the 
BSC and maintenance group. Patients treated with 
gemcitabine  experienced  more  neutropenia  (15% 
vs. 2%), thrombocytopenia (9% vs. 4%), and fatigue 
(5% vs. 2%) than those in the BSC group.
Another gemcitabine maintenance trial was con-
ducted  by  a  French  group  [Intergroupe  Franco-
phone de Cancerologie Thoracique-Groupe Francais 
de  Pneumo-Cancerologie  (IFCT-GFPC)  0502].10 
Patients who achieved at least SD with four cycles of 
induction chemotherapy of gemcitabine and cispla-
tin were randomized to observation, gemcitabine, or 
erlotinib. This study had a unique design in that pem-
etrexed as a second-line therapy was assigned to all 
patients. The primary endpoint of this study was PFS. 
An  independent  review  demonstrated  that  median 
PFS was prolonged in the gemcitabine arm compared 
with the observation arm (3.8 vs. 1.9 months; haz-
ard ratio [HR], 0.55; P , 0.001). Although 69.6% 
of  events  were  observed  at  the  time  of  analysis, 
the HR for OS between the gemcitabine and observa-
tion arms was 0.86 (95% CI, 0.66–1.12). However, 
this trial did not have sufficient statistical power for 
meaningful  survival  differences  due  to  the  small 
number of patients in each arm.
The  PARAMOUNT  study  was  a  randomized 
phase III clinical trial that compared continuation 
maintenance  with  pemetrexed  vs.  placebo  plus 
BSC.11 After four cycles of pemetrexed and cisplatin 
as an induction therapy in 939 patients with non-
squamous cell NSCLC, 539 patients who did not 
progress were randomized in a 2:1 ratio to either 
the  continuation  of  the  single  agent  pemetrexed 
(n = 359) or BSC (n = 180). The primary endpoint 
was  median  PFS,  which  was  significantly  longer 
in  the  pemetrexed  arm  (3.9  months)  than  in  the 
placebo arm (2.6 months) by independent review 
(HR = 0.64, P = 0.0002). The final result of OS is not 
available. Although patients treated with pemetrexed 
  maintenance experienced more fatigue,   anemia, and 
  neutropenia, these   toxicities were confined to less 
than 5% of the study population (Table 1).
switch Maintenance Therapy
Switch maintenance with cytotoxic 
agents
Switch maintenance is defined as the administration 
of an alternative, non-cross-resistant agent, cytotoxic 
chemotherapy, or molecularly targeted agent imme-
diately after induction therapy. This treatment strat-
egy is based on the Goldie-Coldman hypothesis that 
even the smallest detectable cancers contain at least 
one  drug-resistant  clone  and  that  increasing  num-
bers of resistant clones emerge as tumors grow and 
progress.12
Westeel  et  al  conducted  a  randomized  trial  of 
573 patients with stage IIIB/IV NSCLC who were 
treated with mitomycin, ifosfamide, and cisplatin.13 
Among 227 patients who achieved partial response, 
181 patients were randomized to receive either mainte-
nance treatment with weekly vinorelbine for 6 months 
or BSC. There was no difference in either median PFS 
or OS between the maintenance and BSC arms (5 vs. 
3 months P = 0.32; 12.3 vs. 12.3 months P = 0.48, 
respectively). The most common causes of premature 
termination of chemotherapy were progressive disease 
(38%) and toxicity (21%). Moreover, this study needs 
further validation because the role of vinorelbine as a 
second-line treatment has not been established.
Fidias et al performed a landmark switch mainte-
nance therapy study that compared immediate doc-
etaxel maintenance after completion of four cycles of 
induction carboplatin and gemcitabine with observa-
tion and docetaxel given at the time of progression.14 
Of 566 patients, 309 patients who achieved at least SD 
were randomized to either immediate or delayed doc-
etaxel therapy. The primary endpoint was PFS, which 
was significantly longer for the immediate docetaxel 
arm than the delayed arm (P = 0.0001). The median 
OS was better in the immediate docetaxel arm than 
in the delayed arm (12.3 vs. 9.7 months, P = 0.085) 
without  statistical  significance.  Of  note,  94.8%  of 
patients received at least one cycle of immediate doc-
etaxel, whereas only 62.8% of patients in the delayed 
arm received docetaxel at the time of progression. 
The  most  common  reasons  for  not  administering 
docetaxel to patients in the delayed arm were   disease Ahn et al
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investigated as maintenance therapies. Earlier trials 
of  combinations  of  platinum  doublets  with  beva-
cizumab or cetuximab showed survival benefit, but 
these molecularly targeted agents were incorporated 
in  both  the  induction  and  maintenance  phases.16,17 
However, the definitive role of maintenance therapy 
with a single use of a molecularly targeted agent has 
not  yet  been  established.  Here,  only  maintenance 
treatment trials with molecularly targeted agents after 
induction of platinum doublets will be reviewed.
Previous trials with concurrent treatments of gefi-
tinib or erlotinib combined with platinum doublets did 
not show any survival benefit compared with standard 
platinum doublets.18–21 However, the survival benefit 
in  a  subset  of  patients  who  were  maintained  with 
EGFR TKIs prompted investigators to investigate the 
role of EGFR TKIs as a maintenance therapy.
The first landmark study, the sequential   Tarceva 
in  unresectable  non-small  cell  lung  cancer  trial 
  (SATURN) was conducted.22 889 patients who did 
not progress during the four cycles of platinum dou-
blets were randomized to receive either maintenance 
erlotinib or placebo. Patients were stratified by EGFR 
expression, as determined by immunohistochemistry, 
and EGFR gene copy number, as determined by fluo-
rescence in situ hybridization. The primary endpoint 
was PFS. With erlotinib maintenance, there was a 
significant prolongation of both median PFS and OS 
(HR = 0.71, P , 0.0001 and HR = 0.81, P = 0.0088, 
respectively).  However,  no  significant  interactions, 
as determined by biomarkers such as EGFR expres-
sion or EGFR gene copy number, were observed. In 
contrast, a significant PFS benefit from erlotinib was 
observed in patients with EGFR mutations in exon 
19 or 21 compared with those patients with wild-type 
EGFR. The HR was 0.1 (P , 0.0001), which was 
remarkable. There was no difference in OS in these 
groups of patients due to crossover to erlotinib when 
progression occurred. Although 72% of patients in 
the placebo arm received salvage therapy, only 21% 
of patients crossed over to erlotinib. Of note, sur-
vival benefit was seen even in patients with wild-type 
EGFR. However, survival benefit was only confined 
to patients who achieved SD compared with those 
patients who achieved a partial response. Based on 
these data, erlotinib was approved by The European 
Medicines Agency only in patients who achieve SD 
after induction therapy.
  progression,  patient  or  investigator  decision,  and 
death. However, the median OS for patients in the 
immediate arm was almost identical to that of patients 
who received docetaxel in the delayed arm (12.3 vs. 
12.5 months, respectively), suggesting that whether 
patients are treated with a second-line therapy is more 
important than the maintenance therapy itself.
Ciuleanu and colleagues conducted a randomized 
phase III trial that compared pemetrexed maintenance 
with placebo (2:1 ratio) in patients who achieved at 
least SD after one of three platinum-based induc-
tion  chemotherapy  regimens.15  Of  660  patients, 
441 patients received pemetrexed maintenance, and 
222 patients received placebo. The primary endpoint 
was PFS. There were significant differences in median 
PFS  between  the  pemetrexed  and  placebo  arms 
(4.3 vs. 2.6 months, HR 0.6, P = 0.00001). Of note, 
pre-specified histological subgroup analysis showed 
that patients with a non-squamous histology had a 
HR of 0.47 (P = 0.00001) for median PFS. Similarly, 
among patients with a non-squamous histology, the 
median OS for patients receiving pemetrexed main-
tenance therapy was 15.5 months vs. 10.3 months for 
the placebo arm (HR = 0.79, P = 0.012). Although 
67% of patients were treated with various salvage 
therapies in placebo arm, the fact that only 19% of 
patients in placebo arm were treated with pemetrexed 
at the time of progression can raise doubt about the 
exact  role  of  pemetrexed  as  maintenance  therapy. 
Nevertheless, it is the first study to demonstrate sur-
vival benefit from switch maintenance therapy with 
pemetrexed in patients with non-squamous NSCLC. 
Based  on  these  results,  the  Federal  Drug Author-
ity and The European Medicines Agency approved 
pemetrexed  as  a  maintenance  therapy  in  cases  of 
non-squamous NSCLC (Table 2).
Switch maintenance with molecularly 
targeted agents
With advances in understanding lung cancer biology, 
several molecularly targeted agents have been devel-
oped and approved for the treatment of NSCLC, such 
as anti-angiogenic agents that target vascular endothe-
lial  growth  factor  (VEGF),  bevacizumab,  small 
molecule epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor (TKI) (gefitinib or erlotinib), 
and  anti-EGFR  monoclonal  antibody  (cetuximab). 
Due to their low toxicities, these agents have been effectiveness of pharmacotherapies for lung cancer
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In  the ATLAS  study,  743  patients  who  did  not 
progress after four cycles of induction treatment with 
paclitaxel/carboplatin/bevacizumab  were  random-
ized to receive either bevacizumab/erlotinib or bev-
acizumab/placebo.23 The primary end point of PFS 
was met with a HR of 0.72 (P , 0.001). However, 
the difference in median PFS between the two arms 
was only 1 month. The follow-up results showed no 
differences in median OS.
As  part  of  a  switch  maintenance  study  con-
ducted by a French group (Intergroupe Francophone 
de    Cancerologie  Thoracique-Groupe  Francais  de 
Pneumo-Cancerologie [IFCT-GFPC] 0502), patients 
who  achieved  at  least  SD  with  four  cycles  of  an 
induction chemotherapy of gemcitabine and cispla-
tin were randomized to observation, gemcitabine, or 
erlotinib.10 All patients were assigned to pemetrexed 
as a second-line therapy at the time of progression. 
  Independent  review  demonstrated  that  the  median 
PFS was prolonged in the erlotinib arm compared with 
the observation arm (2.9 vs. 1.9 months, HR = 0.82, 
P = 0.002).10
For locally advanced stage III NSCLC, the South-
west  Oncology  Group  0023  trial  was  conducted.24 
Patients who were treated with concurrent chemora-
diotherapy followed by consolidation docetaxel were 
randomized to receive either maintenance gefitinib or 
placebo. However, this trial was also closed early due 
to lack of response and high mortality in the gefitinib 
arm by the data and safety monitoring committee.
Recently, a gefitinib maintenance trial in advanced 
NSCLC  cases  was  conducted  by  Chinese  investi-
gators. Patients who achieved at least SD with four 
cycles of platinum-based chemotherapy were random-
ized to receive either gefitinib (n = 148) or placebo 
(n = 148).25 The primary endpoint was PFS. Patients 
treated  with  gefitinib  showed  prolonged  median 
PFS  compared  with  placebo  (4.8  vs.  2.6  months, 
HR = 0.42, P , 0.0001). Biomarker analysis demon-
strated dramatic differences in median PFS according 
to EGFR mutation status. Patients treated with gefi-
tinib  maintenance  showed  significant  prolongation 
of median PFS compared with placebo (HR = 0.17), 
whereas no differences were noted in patients with 
wild-type EGFR (HR = 0.86). (Table 2)
Angiogenesis is another important target for the 
treatment of NSCLC; thus, many different kinds of 
anti-angiogenic  molecularly  targeted  agents  have 
been  investigated  to  improve  clinical  outcomes  of 
patients with NSCLC. Bevacizumab, a monoclonal 
antibody directed against VEGF, was the first anti-
angiogenic  agent  to  demonstrate  OS  when  com-
bined  with  carboplatin/paclitaxel  compared  with 
  carboplatin/paclitaxel alone.17 Although no survival 
benefit was observed in the Avail study, the median 
PFS was prolonged with the addition of bevacizumab 
to the combination of gemcitabine and cisplatin.26 In 
both studies, bevacizumab was administered as both 
induction and maintenance chemotherapies, making 
it difficult to evaluate the exact role of bevacizumab 
as  a  maintenance  treatment.  Since  then,  a  number 
of small molecule angiogenic inhibitors that target 
VEGF have been investigated in combination with 
platinum-doublets.27–31  Unfortunately,  these  stud-
ies did not show any survival benefit compared with 
standard  combination  chemotherapy.27–31  Recently, 
vandetanib, a dual blocker of EGFR and VEGF TKIs, 
as  a  maintenance  therapy  was  studied  in  patients 
who achieved at least SD after induction chemother-
apy with gemcitabine and cisplatin.32 In this double 
blind, placebo-controlled phase II study, vandetanib 
at a dose of 300 mg/day was administered only in the 
maintenance phase. The primary endpoint was PFS 
at  3  months. The  intention  to  treat  (ITT)  analysis 
included 117 patients (75 in the vandetanib arm and 
42 in the placebo arm). A pre-planned interim analysis 
showed that PFS at 3 months was 29% with placebo, 
leading to the termination of this arm, whereas PFS at 
3 months in the vandetanib arm was 37.5%, allowing 
the second stage to proceed for this arm. The final 
ITT analysis, including second stage, demonstrated 
37.3% of PFS at 3 months for the vandetanib arm.
Discussion
Given  that  most  patients  experience  disease  pro-
gression within 3–4 months after 4–6 cycles of first-
line chemotherapy, maintenance therapy as a new 
  treatment strategy would be a reasonable approach. 
In the trial of Fidias et al,14 only 67% of patients 
were able to receive second-line therapy at the time 
of progression even with intensive follow-up, sug-
gesting  that  patients  who  progress  rapidly  do  not 
have  an  opportunity  to  receive  salvage  therapy. 
This finding might provide a rationale for mainte-
nance treatment. At present, cumulative data from 
large  randomized  clinical    trials  of  maintenance Ahn et al
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therapy and meta-analyses have   demonstrated that 
maintenance  therapies  show  prolongation  of  PFS 
and  improvement  of  OS.33    However,  it  does  not 
appear that maintenance treatments can be applied to 
all NSCLC patients. Therefore, there exists a patient 
population that can benefit from maintenance ther-
apy, whereas there is a patient population that does 
not need maintenance therapy and can enjoy a drug 
holiday. No biomarker is available to select a patient 
population that may benefit from maintenance treat-
ment. We retrospectively analyzed NSCLC patients 
who had achieved non-  progression after four cycles 
of  platinum  doublets  and  were  off  therapy,  but 
could  not  receive  second-line  therapy  at  the  time 
of   progression.34 Among 271 patients, 39 (14.4%) 
patients had not received second-line therapy, pri-
marily due to the rapid progression of disease in the 
lung, brain or bone metastases, or patient refusal. 
Multivariate analysis showed that a smaller decrease 
in target lesions after first-line therapy, a greater than 
7-cm length of the target lesion, and poor PS are all 
associated  with  not  receiving  second-line  therapy, 
suggesting that maintenance therapy might be ben-
eficial for those patients.
Regarding  maintenance  therapy,  several  factors 
should be considered. Whether switch maintenance 
is  better  than  continuation  maintenance  remains 
  controversial. Recent meta-analyses from eight tri-
als  consisting  of  3,736  patients  demonstrated  that 
clinically  substantial  and  statistically  significant 
improvements  in  PFS  were  observed  with  both 
maintenance  strategies;  HR  =  0.53  from  continua-
tion maintenance and HR = 0.67 from switch main-
tenance.33   Additionally, switch maintenance therapy 
substantially improved OS compared with placebo 
or observation (HR = 0.85, P , 0.001). A similar 
trend of improved OS was observed in continuation 
maintenance therapy without statistical significance 
(HR = 0.88, P = 0.124). At present, subgroup anal-
yses revealed no statistically significant differences 
in OS or PFS between switch maintenance therapies 
with cytotoxic agents or EGFR TKIs.
Performance  status  is  another  important  issue 
regarding maintenance therapy, especially continua-
tion maintenance. Of two trials that evaluated gem-
citabine maintenance, clinical benefit was only seen 
in the French trial, not in the trial from Belani et al, 
in  which  64%  of  patients  with  PS2  were  enrolled 
compared  with  only  6%  of  patients  in  the  French 
study, suggesting that patients with poor PS might not 
  benefit from maintenance therapy.
Response status to induction chemotherapy might 
affect the benefit received from maintenance   therapy. 
It  appears  that  patients  who  achieved  a  partial 
response had more benefit from continuation mainte-
nance than those with SD. On the other hand, patients 
who achieved SD might benefit more from switch 
maintenance therapy.
In  terms  of  histology,  the  JMEN  study  demon-
strated survival benefit only in non-squamous NSCLC 
patients who were treated with pemetrexed,15 which 
is consistent with previous studies.35 However, sur-
vival benefit was seen in both adenocarcinoma and 
squamous histologies for erlotinib maintenance in the 
SATURN study.22
The  East-Asian  subgroup  analysis  showed  that 
maintenance  pemetrexed  and  erlotinib  improved 
PFS after first-line treatment but did not show defi-
nite OS benefit. This finding might be attributed to a 
higher proportion of patients who received post-study 
treatment.36  However,  one  should  cautiously  inter-
pret these data due to insufficient statistical power. 
Therefore, to avoid effects of EGFR mutation dilu-
tion, future clinical trials of maintenance therapies 
with EGFR TKIs are needed in NSCLC patients with 
wild-type EGFR.
Quality of life (QOL) is another important issue, 
especially in NSCLC patients who have limited life 
expectancy. Although several studies have addressed 
this  issue,8,14,22  no  definitive  improvement  of  QOL 
with maintenance therapy was reported, although it 
was not reported to have deteriorated.
Not all patients benefit from maintenance therapy. 
Therefore, further research is warranted to develop 
biomarkers for patient selection regarding who may 
benefit  from  maintenance  therapy.  Given  the  high 
cost of molecularly targeted agents, an evaluation of 
cost-effectiveness is also needed.
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